luspatercept (Reblozyl) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA Fast Track FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2563.4400 - $10271.6500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ace-536 | luspatercept

Organizations (18)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (2)


 

Anemia (approved 2020)

beta-Thalassemia (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Anemia (Phase 4)

Anemia, Aplastic (Phase 2)

beta-Thalassemia (Phase 4)

Blood Transfusion (Phase 4)

Erythrocyte Transfusion (Phase 3)

Myelodysplastic Syndromes (Phase 4)

Myeloproliferative Disorders (Phase 3)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue